Health Ministry Expands Curbs on Fixed-Dose Combination Cold Medicines for Children

Gist The Union Health Ministry has expanded its restrictions on all fixed-dose combination FDC medicines containing chlorpheniramine maleate and phenylephrine hydrochloride, prohibiting their use in children under four years of age. This regulatory move mandates strict warning labels on packages and promotional literature, reflecting concerns over severe adverse effects, dosing vulnerabilities, and a lack of proven efficacy. For an aspirant, this development highlights the regulatory framework governing pharmaceuticals in India, the role of statutory bodies in evaluating drug safety, and the ongoing public health effort to curb the irrational use of multi-ingredient medicines in paediatric care. Background A Fixed-Dose Combination FDC includes two or more active pharmaceutical ingredients in a single dosage form. While convenient, they often lack evidence of combined efficacy and can compound side effects, particularly in vulnerable populations like infants. The restriction is enforced under Section 26A of the Drugs and Cosmetics Act, 1940 , which empowers the Central Government to regulate, restrict, or prohibit the manufacture, sale, or distribution of drugs in the public interest. The Drugs Technical Advisory Board DTAB is the highest statutory decision-making…